Prostate cancer is the most common malignancy in men in the US. Both at diagnosis and throughout the disease progression it can metastasize to multiple organs (bone and lymph being the most common). Effusions (either pleural or abdominal) are relatively uncommon, but usually occur as a result of soft tissue lesions. Herein we report on a patient with androgen independent prostate cancer and an elevated PSA with disease con®ned to ascites of the abdomen.
Introduction
Carcinoma of the prostate is the most common cancer in men in the United States, with an estimated 184,500 new cases in 1999 and 39,000 deaths. Following failure of hormonal therapy, treatment options are limited, with no regimen being shown to prolong survival. Approximately 20% of patients with androgen independent disease have metastatic lesions detectable on CT scan with over 90% having bone metastases that are followable on nuclear imaging. Effusions (either pleural or abdominal) are relatively uncommon in this disease, but usually occur as a result of soft tissue lesions. In this report, we present a patient with androgen independent disease and an elevated prostate speci®c androgen (PSA) who had failed multiple therapeutic maneuvers with disease con®ned to ascites.
Case Report
JF is a 70-y-old White male who was initially diagnosed with adenocarcinoma of the prostate (Gleason grade 4 5 9/10) in April 1994. His PSA at that time was 128 ng/ml. In June 1994, the patient received 6700 cGy of external radiation, with a subsequent decline in PSA to less than 2 ng/ml. However, 3 y later his PSA was found to be 11.1 ng/ml, without evidence of metastatic disease on either CT scan or bone scan. In November 1997, he was started on combined androgen blockade (leuprolide and utamide), but his PSA response lasted for less than 1 y. In July 1998,¯utamide was discontinued and bicalutamide was initiated. In September 1998, his PSA was noted to have continued to increase (9.1 ng/ml) and, thus, bicalutamide was discontinued. In October 1998, a repeat CT scan and bone scan failed to document metastatic disease. Furthermore, there was no evidence of lymphadenopathy on physical exam. In October 1998, the patient was enrolled on an NCI approved trial which was evaluating thalidomide in patients with refractory prostate cancer. Biopsy at the time of enrollment demonstrated residual/recurrent adenocarcinoma within the prostate and a serum PSA of 262 ng/ml. Neuroendocrine stains were negative in the primary tumor.
Five days into treatment, the patient was noted to have increased abdominal bloating and fullness with increasing lower extremity adema without pain. The patient had been taking hydrochlorothiazide for hypertension for many years, thus his dose was increased from 25 mg per day to 50 mg per day. Two weeks later he was found to have abdominal ascites and a weight gain of 7.3 kg.
A venogram failed to show an inferior vena cava thrombosis. A CT scan of the abdomen showed no evidence of adenopathy, or compression of the lymphatic or the venous system. It was thought that his ascites was most likely due to¯uid retention secondary to thalidomide. He continued on hydrochlorothiazide along with furosemide 40 mg per day. Later that month, his ascites worsened resulting in shortness of breath. Examination of the abdomen revealed a large distended abdomen, hyperresonant to percussion with the presence of shifting dullness and¯uid thrill. The lower extremities were found to have 1 edema up to the ankles. His neurological examination was normal except for decreased vibration sense in the lower extremities. His LFTs were normal (alkaline phosphatase 94 U/l, alanine aminotransferase 27 U/l, aspartate aminotransferase 23 U/l, total bilirubin 0.8 mg/dl, lactate dehydrogenase 184 U/l) and his albumin was 184 g/dl. Repeat CT scan showed that the patient had fat stranding consistent with carcinomatosis. A paracentesis was done, and the examination of the ascitic¯uid revealed a glucose of 121 mg/dl, albumin of 2.8 g/dl and an albumin gradient of less than 1.1. The ascitic¯uid revealed malignant cells (Figure 1 ), which were consistent with poorly differentiated carcinoma of the prostate. Staining for PSA and prostatic acid phosphatase was also positive for cells in the peritoneal¯uid con®rming the diagnosis of ascites secondary to carcinoma of the prostate (see Figures 2 and 3) . Two months later, his bone scan and CT scan were still negative, but his PSA continued to rise. The patient was removed from study due to progressive disease. 
Discussion
Carcinoma of the prostate can metastasize to nearly every organ, but metastasis without osseous involvement is extremely rare. Arnheim and others have described postmortem cases of patients with prostate cancer 1 ± 4 ( Table  1 ). The most common sites of metastatic disease include bones, lymph nodes and lungs. Adrenal gland, kidney, brain, pancreas, genitalia and breasts are relatively uncommon sites of metastases. Malignant effusions, whether pleural or peritoneal, are extremely rare clinical manifestations of prostate cancer. Broghamer et al described a series of 33 patients with prostate cancer, the peritoneal¯uid involvement in most cases was caused by a second primary malignancy or concomitant reactive condition. 5 Furthermore, review of the medical literature failed to ®nd any case of androgen independent prostate cancer in which ascites is the only manifestation. We did identify six cases in which the initial presentation at the time of diagnosis was one or more effusions (Table 2 ). 6 ± 10 Invasion of the mesothelial lining by malignant cells is considered to be a triggering factor in the pathogenesis of a body cavity effusion such as ascites. Neoplastic cells in an effusion may have exfoliated from the primary lesion as evidenced by the positive cytological examination of these¯uids. It is also suggested that the effusion may develop secondary to the obstruction of lymphatics, or that it may be the result of prostatic lymphatic carcinomatosis. Other benign and malignant etiologies should be considered in these cases. A case of chylous ascites as a presenting sign of prostate adenocarcinoma has also been reported. 6 In that report, the patient presented with enlarged retroperitoneal lymph nodes and wide dissemination of the cancer of the prostate, development of chylous ascites, which was thought to be secondary to diffuse metastases to periaortic lymph nodes, and regional lymphatics draining the prostate carcinoma. 6 Thalidomide was initially thought to be the cause of the patient's ascites and leg edema. The preliminary data from our phase II trial involving thalidomide revealed peripheral edema in approximately 50% of cases, but clinically prominent ascites or other effusions have not been seen.
However, immunohistochemical assessment of PSA and prostatic acid phosphatase in malignant cells from the ascites¯uid strongly suggests that prostate cancer may be the primary cause of third space¯uid in this circumstance. 12, 13 This ®nding emphasizes the importance of determining the etiology of adverse events in early trials of novel agents, and not simply assuming that a clinical symptom is drug related.
Malignant effusions in cases of prostate carcinoma have been noted not to resolve with endocrine therapy even in patients without prior hormonal ablation. 7 However, Hefner et al reported a case in which a patient had a poor response to diethylstilbestrol diproprionate therapy in resolving pleural effusions on two occasions. 7 Calton et al reported a response to orchiectomy with control of ascites for 9 months in which no other immediate therapy was instituted. 8 Malignant effusions, whether peritoneal or pleural, are rare with carcinomas of prostatic origin and much less so in patients without osseous or lymph node involvement.
In conclusion, malignant effusions like ascites are potential complications of carcinoma of the prostate. Although these effusions may constitute the initial manifestation of prostatic adenocarcinoma, such effusions may be the only signs of recurrence of prostatic disease following hormonal ablation. Prostatic cancer is a common disease of the elderly male and presents typically, either with obstructive uropathy or disease in the axial skeleton. However, an unusual presentation like malignant effusions may be encountered. Therefore, urologists, oncologists and primary physicians should be aware of this complication of prostatic disease. Immunohistochemical methods should be employed in sorting out the tumor origin, since these malignant effusions have a signi®cant impact on morbidity and mortality.
